Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study

Ryota Tashiro; Hitoshi Kawazoe; Kanako Mamishin; Keisuke Seto; Ryoko Udagawa; Yoshimasa Saito; Hironobu Hashimoto; Tatsunori Shimoi; Kan Yonemori; Masahito Yonemura; Hiroyuki Terakado; Toshikatsu Kawasaki; Tetsuya Furukawa; Tomonori Nakamura

doi:10.3389/fonc.2022.898150

Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study

Front Oncol. 2022 Oct 4:12:898150. doi: 10.3389/fonc.2022.898150. eCollection 2022.

Authors

Ryota Tashiro^{1

2}, Hitoshi Kawazoe^{2

3}, Kanako Mamishin⁴, Keisuke Seto⁵, Ryoko Udagawa¹, Yoshimasa Saito¹, Hironobu Hashimoto¹, Tatsunori Shimoi⁶, Kan Yonemori⁶, Masahito Yonemura⁴, Hiroyuki Terakado⁵, Toshikatsu Kawasaki⁴, Tetsuya Furukawa¹, Tomonori Nakamura^{2

3}

Affiliations

¹ Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
² Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.
³ Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.
⁴ Department of Pharmacy, National Cancer Center Hospital East, Chiba, Japan.
⁵ Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
⁶ Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Abstract

Background: Olaparib-induced anemia is a frequently occurring complication in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and is associated with a marked deterioration in patients' health-related quality of life. This study aimed to clarify patient-specific risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy in a real-world setting.

Methods: This multicenter, retrospective, observational study enrolled consecutively presenting patients with advanced ovarian or breast cancer who received olaparib monotherapy as maintenance or palliative treatment between April 2018 and December 2020 at three participating medical institutions in Japan. The primary endpoint was patient-associated risk factors underlying the onset of grade ≥3 anemia from olaparib treatment initiation to 90 days after treatment. Receiver operating characteristic curves were constructed and univariable and multivariable logistic regression analyses were performed to evaluate the association between patient-associated risk factors and grade ≥3 anemia.

Results: Of 113 patients evaluated in this study, 32.7% (n = 37) had grade ≥3 anemia. Multivariable logistic regression analysis revealed that low baseline red blood cell (RBC) count (<3.3 × 10⁶ cells/μL), low baseline hematocrit level (<35%), low baseline hemoglobin level (<11.6 g/dL), and breast cancer susceptibility (BRCA1/2) mutation were significantly associated with the onset of grade ≥3 anemia (adjusted odds ratio [OR], 3.39; 95% confidence interval [CI], 1.28-9.62; P = 0.017, adjusted OR, 3.63; 95% CI, 1.28-11.64; P = 0.021, adjusted OR, 3.89; 95% CI, 1.39-12.21; P = 0.014, and adjusted OR, 4.09; 95% CI, 1.55-11.67; P = 0.006, respectively).

Conclusions: Our findings suggest that low baseline RBC count, low baseline hematocrit level, and low baseline hemoglobin level might be the patient-associated risk factors for severe anemia induced by olaparib monotherapy. Additionally, BRCA1/2 mutation was suggested to be a patient-related risk factor for anemia regardless of severity. Therefore, applying these patient-associated risk factors would help classify and screen patients at risk of severe anemia.

Keywords: breast cancer susceptibility (BRCA) gene; olaparib (Lynparza™); red blood cell count (RBC); risk factor; severe anemia.